Zoledronic acid: new indication. No therapeutic advantage in postmenopausal osteoporosis.
In the absence of relevant comparisons, it remains to be shown whether zoledronic acid, given as a yearly intravenous infusion, has any therapeutic advantage over other bisphosphonates.